These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8395133)

  • 1. Drug resistance associated with altered DNA topoisomerase II.
    Beck WT; Danks MK; Wolverton JS; Kim R; Chen M
    Adv Enzyme Regul; 1993; 33():113-27. PubMed ID: 8395133
    [No Abstract]   [Full Text] [Related]  

  • 2. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
    Ritke MK; Roberts D; Allan WP; Raymond J; Bergoltz VV; Yalowich JC
    Br J Cancer; 1994 Apr; 69(4):687-97. PubMed ID: 8142256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance.
    Beck WT
    J Natl Cancer Inst; 1989 Nov; 81(22):1683-5. PubMed ID: 2553990
    [No Abstract]   [Full Text] [Related]  

  • 4. Circumvention of atypical multidrug resistance with tumor necrosis factor.
    Cimoli G; Valenti M; Parodi S; De Sessa F; Russo P
    Jpn J Cancer Res; 1994 Feb; 85(2):135-8. PubMed ID: 8144394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yeast as a genetic model system for studying topoisomerase inhibitors.
    Nitiss JL
    Adv Pharmacol; 1994; 29B():201-26. PubMed ID: 8996609
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors.
    Davies SL; Bergh J; Harris AL; Hickson ID
    Br J Cancer; 1997; 75(6):816-21. PubMed ID: 9062401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recent progress in the study of the mechanism of resistance to DNA topoisomerase inhibitors].
    Ishida R; Andoh T
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):952-61. PubMed ID: 8002633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA.
    Gudkov AV; Zelnick CR; Kazarov AR; Thimmapaya R; Suttle DP; Beck WT; Roninson IB
    Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3231-5. PubMed ID: 8386368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
    Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
    Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered DNA topoisomerase II in multidrug resistance.
    Beck WT; Danks MK; Wolverton JS; Granzen B; Chen M; Schmidt CA; Bugg BY; Friche E; Suttle DP
    Cytotechnology; 1993; 11(2):115-9. PubMed ID: 7764055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity.
    Mao Y; Yu C; Hsieh TS; Nitiss JL; Liu AA; Wang H; Liu LF
    Biochemistry; 1999 Aug; 38(33):10793-800. PubMed ID: 10451375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II.
    Beck WT; Danks MK; Wolverton JS; Chen M; Granzen B; Kim R; Suttle DP
    Adv Pharmacol; 1994; 29B():145-69. PubMed ID: 8996606
    [No Abstract]   [Full Text] [Related]  

  • 13. Topoisomerase II in multiple drug resistance.
    Hofmann GA; Mattern MR
    Cytotechnology; 1993; 12(1-3):137-54. PubMed ID: 7765323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yeast systems for demonstrating the targets of anti-topoisomerase II agents.
    Nitiss JL; Nitiss KC
    Methods Mol Biol; 2001; 95():315-27. PubMed ID: 11089243
    [No Abstract]   [Full Text] [Related]  

  • 15. A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents.
    Blower TR; Bandak A; Lee ASY; Austin CA; Nitiss JL; Berger JM
    Nucleic Acids Res; 2019 Sep; 47(15):8163-8179. PubMed ID: 31287876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance.
    Liu LF; D'Arpa P
    Important Adv Oncol; 1992; ():79-89. PubMed ID: 1316311
    [No Abstract]   [Full Text] [Related]  

  • 17. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation.
    Madelaine I; Prost S; Naudin A; Riou G; Lavelle F; Riou JF
    Biochem Pharmacol; 1993 Jan; 45(2):339-48. PubMed ID: 8382060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to topoisomerase II poisons: is the answer in the promoter?
    Kaufmann SH
    Leuk Res; 1997; 21(11-12):1033-6. PubMed ID: 9444936
    [No Abstract]   [Full Text] [Related]  

  • 20. Alchemix, p53 and topoisomerase.
    Grand RJ; Stewart GS
    Aging (Albany NY); 2015 Sep; 7(9):601-2. PubMed ID: 26388618
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.